Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30552358 | 1.00 | CRBN (0.56) | CRBNDDB1GAAGFERKDM4E | |
| SCHEMBL29022614 | 0.83 | CRBN (0.48) | CRBNDDB1ALDH1A1SCN5ASCN9A | |
| SCHEMBL21383782 | 0.81 | CRBN (0.45) | CRBNDDB1GAAGFERKDM4E | |
| SCHEMBL29603792 | 0.81 | CRBN (0.45) | CRBNDDB1GAAGFERKDM4E | |
| SCHEMBL17350152 | 0.80 | PDE7A (0.42) | CRBNGAAKDM4EALDH1A1 | |
| SCHEMBL26226526 | 0.80 | MAPK1 (0.48) | CRBNDDB1 | |
| SCHEMBL2897645 | 0.77 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL19225163 | 0.77 | PDE7A (0.47) | CRBNGAAKDM4EALDH1A1 | |
| SCHEMBL4979700 | 0.76 | OPRM1 (0.54) | — | |
| SCHEMBL2315258 | 0.76 | OPRM1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CRBN 904/4885DDB1 2044/4885GAA 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.